CEACAM5 and colorectal cancer: These results demonstrate that 177Lu-DOTA-M5A mediates dose-dependent and CEA-specific therapeutic effects in CEA-positive colorectal cancer models and may potentially lead to a promising conjugate to pursue for RIT of CEA-positive colorectal cancer.